Dr. Passo has received consultancy fees, speaking fees, and/or honoraria (less than $10,000) from Pfizer and is a pregabalin site principal investigator for Pfizer.
Utility of the PedsQL Rheumatology Module as an Outcome Measure in Juvenile Fibromyalgia†
Article first published online: 28 OCT 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 11, pages 1820–1827, November 2013
How to Cite
Joffe, N. E., Lynch-Jordan, A., Ting, T. V., Arnold, L. M., Hashkes, P. J., Lovell, D. J., Passo, M. H., Powers, S. W., Schikler, K. N. and Kashikar-Zuck, S. (2013), Utility of the PedsQL Rheumatology Module as an Outcome Measure in Juvenile Fibromyalgia. Arthritis Care Res, 65: 1820–1827. doi: 10.1002/acr.22045
ClinicalTrials.gov identifier: NCT00086047.
- Issue published online: 28 OCT 2013
- Article first published online: 28 OCT 2013
- Accepted manuscript online: 17 MAY 2013 02:04PM EST
- Manuscript Accepted: 6 MAY 2013
- Manuscript Received: 8 NOV 2012
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: R01-AR-050028
The PedsQL rheumatology module is currently the only available measure of disease-specific quality of life for children and adolescents with juvenile fibromyalgia (FM), but limited information has been published about the psychometric properties of the instrument, specifically in juvenile FM. The objective of this study was to assess the reliability, validity, and sensitivity to change of the 5 scales (pain and hurt, daily activities, treatment, worry, and communication) of the patient and parent proxy versions of the PedsQL rheumatology module in the context of a randomized controlled trial in juvenile FM.
The entire PedsQL rheumatology module was administered as a supplementary outcome measure at baseline, posttreatment, and 6-month followup assessments of 114 children and adolescents with juvenile FM enrolled in a trial testing the efficacy of cognitive–behavioral therapy.
Internal consistency reliabilities for the scales were adequate to strong (Cronbach's α = 0.68–0.86). Parent proxy and child reports on most scales (except for daily activities and communication) showed moderate correlations (Spearman's r = 0.33–0.45). Support for construct validity was found by comparing child and parent reports with other related measures of pain and functioning (visual analog scale pain ratings and the Functional Disability Inventory). Finally, sensitivity to change was demonstrated by significant changes in 4 of the 5 scales (excluding the daily activities scale) after treatment.
The PedsQL rheumatology module generally appears to have good utility for use in juvenile FM patients, but there are some caveats to the interpretation of specific scales in this population.